Medicine and Dentistry
Sorafenib
100%
Combination Therapy
100%
Clear Cell Renal Cell Carcinoma
100%
Kidney Metastasis
100%
Sunitinib
100%
Progression Free Survival
50%
Clinical Study
50%
Phosphotransferase Inhibitor
50%
Vasculotropin
50%
Temsirolimus
50%
Cytokine
50%
Mechanistic Target of Rapamycin
50%
Pharmacology, Toxicology and Pharmaceutical Science
Renal Cell Carcinoma
100%
Combination Therapy
100%
Sorafenib
100%
Sunitinib
100%
Kidney Metastasis
100%
Clinical Study
50%
Mammalian Target of Rapamycin
50%
Cytokine
50%
Vasculotropin
50%
Phosphotransferase Inhibitor
50%
Progression Free Survival
50%
Temsirolimus
50%